Iryna Drozd/iStock via Getty Images
- BridgeBio (NASDAQ:BBIO) has received FDA Regenerative Medicine Advanced Therapy designation for its AAV9 gene therapy candidate BBP-812 for the treatment of patients with Canavan disease, a fatal neurodegenerative disorder.
- The company said it plans to leverage the benefits of the designation to establish an accelerated pathway for the treatment, according to a statement.
- The therapy has also been granted Orphan Drug, Rare Pediatric Disease, and Fast Track Designations by the FDA, as well as Orphan Drug Designation by the European Medicines Agency.
Source link
